Cronos Group Stock Today
| CRON Stock | USD 1.93 0.05 2.66% |
Performance0 of 100
| Odds Of DistressLess than 45
|
Cronos is selling at 1.93 as of the 30th of January 2025; that is 2.66 percent increase since the beginning of the trading day. The stock's open price was 1.88. Cronos has 45 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 31st of December 2024 and ending today, the 30th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of July 2016 | Category Healthcare | Classification Health Care |
It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada. The company has 382.3 M outstanding shares of which 3.4 M shares are currently shorted by private and institutional investors with about 5.07 trading days to cover. More on Cronos Group
Moving together with Cronos Stock
Moving against Cronos Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cronos Stock Highlights
| CEO President | Michael JD | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cannabis (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Cronin Group Plc | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Cannabis, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCronos can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cronos' financial leverage. It provides some insight into what part of Cronos' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Cronos Group (CRON) is traded on NASDAQ Exchange in USA. It is located in 111 Peter Street, Toronto, ON, Canada, M5V 2H1 and employs 356 people. Cronos is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 718.71 M. Cronos Group conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 382.3 M outstanding shares of which 3.4 M shares are currently shorted by private and institutional investors with about 5.07 trading days to cover.
Cronos Group currently holds about 944.89 M in cash with (42.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.5, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cronos Probability Of Bankruptcy
Ownership AllocationCronos holds a total of 382.3 Million outstanding shares. Cronos Group retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cronos Ownership Details
Cronos Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Qube Research & Technologies | 2024-09-30 | 522.9 K | |
| Geode Capital Management, Llc | 2024-09-30 | 513.6 K | |
| Citadel Advisors Llc | 2024-09-30 | 511.8 K | |
| Penserra Capital Management, Llc | 2024-09-30 | 507.9 K | |
| Goldman Sachs Group Inc | 2024-09-30 | 472.8 K | |
| Kerrisdale Advisers, Llc | 2024-09-30 | 458.2 K | |
| Swiss National Bank | 2024-09-30 | 415.4 K | |
| Intact Investment Management, Inc. | 2024-09-30 | 377.9 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 374.6 K | |
| Chescapmanager Llc | 2024-09-30 | 8 M | |
| Vanguard Group Inc | 2024-09-30 | 7.5 M |
Cronos Historical Income Statement
Cronos Stock Against Markets
Cronos Corporate Management
| James III | Controller VP | Profile | |
| Arye Weigensberg | Senior Development | Profile | |
| Shayne Laidlaw | Director Strategy | Profile | |
| Terry Doucet | General Secretary | Profile | |
| Kevin Gifford | VP Fin | Profile | |
| James Holm | Chief Officer | Profile | |
| Anna Shlimak | Senior Strategy | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cronos Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cronos. If investors know Cronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cronos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.144 | Earnings Share (0.12) | Revenue Per Share | Quarterly Revenue Growth 0.46 | Return On Assets |
The market value of Cronos Group is measured differently than its book value, which is the value of Cronos that is recorded on the company's balance sheet. Investors also form their own opinion of Cronos' value that differs from its market value or its book value, called intrinsic value, which is Cronos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cronos' market value can be influenced by many factors that don't directly affect Cronos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cronos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cronos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cronos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.